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Window-of-opportunity triala b s t r a c t
Tumour hypoxia and its molecular responses have been shown to be associated with poor prognosis.
Detection of hypoxia, preferably in a non-invasive manner, could therefore predict treatment outcome
and serve as a tool to individualize treatment. This review gives an overview of recent literature on
hypoxia imaging markers currently used in clinical trials. Furthermore, recent progress made in targeting
hypoxia (hypoxia-activated prodrugs) or hypoxia response (carbonic anhydrase IX inhibitors) is summa-
rized. Last, window-of-opportunity trials implementing non-invasive imaging are proposed as an impor-
tant tool to prove anti-tumour efficacy of experimental drugs early during drug development.
 2015 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 116 (2015) 352–357
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).It is well established that tumours are not a collection of rela-
tively homogeneous cancer cells, but act as organs with a complex-
ity that might even exceed that of healthy tissues. Therefore to
understand the biology of a tumour both the different individual
cell types within a tumour as well as its microenvironment need
to be studied [1]. Within this review, we will focus on hypoxia, a
common characteristic of solid tumours, which has been associ-
ated with poor prognosis [2]. Detection of hypoxia, preferably in
a non-invasive manner, could predict treatment outcome and serve
as a tool to support treatment decisions. Such non-invasive imag-
ing approaches that are routinely available in clinical practice
including positron emission tomography (PET), magnetic reso-
nance imaging (MRI) and perfusion computed tomography (CT)
are able to accurately and reliably image hypoxia in tumours. Over
the last decade, these diagnostic techniques are developing into
versatile tools integrated in treatment monitoring, outcome pre-
diction and treatment targeting. A meta-analysis evaluating the
relationship between hypoxia imaging and outcome after radiation
treatment demonstrated a uniform tendency for poor response
when tumours were hypoxic. This was not only observed forwidely used hypoxic PET tracers, but also when hypoxia was indi-
rectly evaluated using perfusion-CT or DCE-MRI [3].
While the prognostic significance of tumoural hypoxia on out-
come has been established more than two decades ago only
recently compounds are being tested in clinical trials that enable
monitoring and selective elimination of hypoxic tumours cells.
Here we will provide an update on the current status of hypoxia
imaging agents and strategies to combat tumour hypoxia.Hypoxia PET imaging tracers
Multiple PET tracers suitable for the detection of hypoxia have
been developed, validated and shown to exhibit different
characteristics. The ideal hypoxia tracer has complete clearance
of unbound tracer at time of imaging, thus only bound in oxygen
deprived tissues resulting in high signal to noise ratios [3].
We recently reviewed the PET hypoxia tracers that were validated
in preclinical and clinical studies and reported accurate
quantification methods and clinical applications [4]. The most
investigated PET hypoxia tracer is fluoromisonidazole (FMISO).
However, due to concerns regarding FMISO stability, metabolite
formation and slow clearance properties [5,6], alternative hypoxia
PET tracers with different clearance and hydrophilicity characteris-
tics have been developed trying to overcome these limitations:
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(FETNIM) and fluorinated etanidazole derivatives (EF1, EF3, EF5),
which all have been extensively reviewed previously [3,4,7].
More recently, the hydrophilic flortanidazole (HX4), with pre-
ferred pharmacokinetics and clearance properties, has been syn-
thesized through click-chemistry [8] showing 82% intact and 84%
unmetabolized tracer at 2 h post injection (h p.i.) in plasma and
urine respectively [9]. HX4 has been evaluated in a preclinical
rhabdomyosarcoma rat tumour model, where binding was causally
dependent on tumoural oxygenation status. Furthermore, a signif-
icant spatial relationship at tumour-microregional level between
HX4 distribution and the exogenous hypoxia marker pimonidazole
staining was observed [10,11]. Studies in primates and healthy vol-
unteers [9] and in patients with histologically proven solid cancer
[12] provided evidence for a good safety profile. Recently, in non-
small cell lung cancer patients, image contrast was found to be
superior 4 h p.i. compared with earlier time points and uptake pat-
terns were strongly correlated between two scans [13]. Overlap
studies between HX4 and the metabolism tracer FDG indicated
that on average 24% of the hypoxic volume is outside the FDG vol-
ume [14]. Similar results have been obtained for head and neck
cancer patients [15], suggesting that hypoxia PET imaging provides
complementary information to FDG imaging.
Due to the large heterogeneity in uptake, differences in tumour
and animal models, different time points of imaging and anaesthe-
sia observed in the literature, it is difficult to compare different
hypoxia markers. Although characterization of new hypoxia mark-
ers should be preferably performed in multiple cancer models,
highly additive data can be expected from comparisons of different
tracers within the same tumour models [3,11]. Recently, we per-
formed a comparative study characterizing the clinically approved
hypoxia markers FMISO, FAZA and HX4 on tumour to blood ratio
(TBR), reproducibility and reversibility within a rat rhabdomyosar-
coma model [16]. Blood clearance for FAZA and HX4 became sim-
ilar 3 h p.i., while for FMISO as expected clearance from normal
tissues was significantly lower. Differences in tumour uptake
resulted in significantly higher TBR for HX4 compared to the other
tracers. Reproducibility and spatial overlap between two PET
acquisitions over a 48 h time period was high for both FMISO
and HX4. Furthermore, decreasing the hypoxic fraction using car-
bogen resulted in loss of FMISO uptake, while increased hypoxia
achieved by breathing 7% oxygen, further enhanced FAZA and
HX4 uptake. Another study performed a similar comparison in a
SQ20b head and neck xenograft mouse model and found similar
tumour to muscle ratios for FMISO, FAZA and HX4 [10]. However,
these results were obtained at 80–90 min p.i., a time point which
is probably too early for evaluation since normal tissue clearance
is still ongoing. A comparative study in head and neck cancer
patients found similar tumour to muscle ratios for HX4 imaging
at 1.5 h p.i. and FMISO imaging at 2 h p.i. [17]. For HX4 higher
uptake and increasing ratios would be expected at later time points
based on our clinical results [13]. Recently a simulation study,
comparing FMISO, FAZA and HX4 based on their respective physi-
cal and chemical properties, revealed that tracer clearance and
diffusion are the major parameters influencing image contrast.
Highest clearance and image contrast was observed for HX4, but
also the largest patient-to-patient variation, which might be a
concern for clinical imaging to define tumour hypoxia based on a
reliable threshold value [18].
Current available tracers have proven to be reliable for evalua-
tion of tumour hypoxia, although with inherent problems resulting
in clinical limitations. Alternative tracers, such as HX4, are promis-
ing with respect to deliver higher contrast images, whereas FMISO
remains a robust reproducible hypoxia marker. It is not inconceiv-
able that more tracers will be developed; but currently existingPET tracers should rather be used in clinic with standardized pro-
tocols enabling comparisons between different institutes. Further-
more, applicability and clinical validation should be proven in
multiple cancer types and tracers need be tested with respect to
their prognostic and predictive value.
Hypoxia targeting
The compelling evidence for hypoxia in tumour tissue and its
therapeutic importance makes hypoxia a high priority target for
cancer therapy. Bioreductive prodrugs selectively activated under
hypoxia and drugs that inhibit molecular targets in hypoxic cells
(vide infra) are currently extensively investigated. A recent over-
view described the challenges and opportunities of these strategies
[19]. The clinically most advanced hypoxia-activated prodrug is
tirapazamine (TPZ). Although promising results have been
reported in a number of Phase 2 trials, TPZ failed in several Phase
3 clinical trials since no survival benefit was observed when incor-
porated into standard therapy regimens. Possible explanations are
its poor tumour penetration, low in vivo potency at tolerable doses
and unacceptable toxicity levels and lack of patient selection with
high levels of tumour hypoxia [20]. A more potent hypoxia-
activated prodrug currently undergoing early clinical testing is
TH-302. It is a 2-nitroimidazole conjugated to bromo-
isophosphoramide mustard, which is released and activated upon
very low levels of oxygen [21] and diffuses to surrounding cells
creating a cytotoxic bystander effect [19]. TH-302 displayed clini-
cal activity when used as single agent, which makes it unique com-
pared to earlier generation hypoxia-activated cytotoxins which
demonstrate anti-tumour activity only when used in combination
with radiation or chemotherapy [22]. Furthermore, TH-302 efficacy
was correlated with the hypoxic fraction across different tumour
models [23–26]. Phase 1 trials have proved TH-302 safety with
nausea, vomiting and fatigue as the most frequently occurring tox-
icities. Other trials successfully combined TH-302 with doxoru-
bicin in patients with advanced soft tissue sarcoma [27] or with
gemcitabine in patients with advanced pancreatic cancer [28]. A
phase 3 double-blind, placebo-controlled trial has been initiated
in which patients with advanced pancreatic cancer were random-
ized to gemcitabine combined with TH-302 or placebo [29].
Recently our group has evaluated the efficacy of TH-302 in a rat
rhabdomyosarcoma and a human H460 xenograft model, using
growth delay as endpoint. TH-302 in both models significantly
inhibited tumour growth and markedly sensitized tumours to
radiation. Furthermore, the therapeutic effect of TH-302 was
dependent on the tumour oxygenation status prior to local radio-
therapy that was modified by either carbogen (to improve oxy-
genation) or low oxygen containing gas (to increase hypoxia)
breathing [30].
Increasing tumour oxygenation has shown potential for
improving radiotherapy efficacy in several randomized clinical tri-
als [31,32]. In spite of positive results, these strategies using hyper-
baric oxygen or carbogen combined with vasodilating agents have
not gained clinical traction due to practical limitations, toxicity and
relatively modest clinical benefit [33]. An alternative strategy to
achieve improved tumour oxygenation is to decrease cellular oxy-
gen consumption using for example metformin, an inhibitor of the
mitochondrial NADH dehydrogenase, also known as complex 1,
activity in the mitochondrial electron transport respiration chain
[34]. Recently, it has been demonstrated that metformin increases
tumour response to radiotherapy, through a reduction in oxygen
consumption and improved tumour oxygenation [35]. For future
personalized cancer medicine, evaluation of hypoxia biomarkers
and patient stratification will be essential to apply hypoxia target-
ing treatments to change radiotherapy response.
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As tumours progress from an early to later stage disease, supply
of oxygen becomes limited. Cancer cells must therefore alter their
metabolism to an anaerobic glycolytic phenotype, resulting in a
less efficient energy production and intracellular acidosis. In order
to survive cancer cells must adapt to this acidic microenvironment,
which helps promote metastases [36]. One of the important
molecular responses to hypoxia is the stabilization of the hypoxia
inducible factor (HIF)-1a, enabling interaction with HIF-1b. The
complex translocates to the nucleus where it binds to hypoxia
responsive elements (HRE) in the promoter region of target genes,
such as vascular endothelial growth factor (VEGF), glucose trans-
porters 1 (GLUT-1) and carbonic anhydrase IX (CAIX) [37]. CAIX
as well as other membrane transporters, like the sodium-proton
exchanger 1 (NHE-1) and the monocarboxylate transporters
(MCT), are upregulated to counteract the hypoxia-induced intra-
cellular acidosis. CAIX is a tumour specific dimeric membrane
bound zinc metallo-enzyme, which catalyses the reversible hydra-
tion of carbon dioxide to bicarbonate and a proton to help maintain
the cells pH homeostasis [38]. High tumoural CAIX expression has
been associated with poor prognosis, tumour progression and
aggressiveness [39]. Inhibition of its function would therefore be
a promising anticancer approach to target the hypoxic compart-
ment of tumours.CAIX imaging tracers
A molecular imaging approach based on selective ligands to
accessible proteins overexpressed at sites of hypoxia is desired.
Such an agent could help physicians to decide which patients
would benefit from adjuvant hypoxia-targeted therapy, e.g. anti-
CAIX therapy. One strategy is using antibodies or antibody frag-
ments targeted against transmembrane CAIX expression. The
highly specific antibody M75 recognizes the extracellular
proteoglycan-like domain of CAIX and is used for Western blotting
and immunohistochemistry [40]. Specific accumulation of iodine-
125 radiolabelled derivative has been observed in HT29 tumour-
bearing mice [41]. Independently, the monoclonal G250 antibody
was developed as a biomarker for renal cell carcinoma [42]. A chi-
meric version of G250 (cG250) has been radiolabelled with iodine-
124, zirconium-89 or indium-111 for diagnostic purposes [43].
However, no apparent correlation has been observed between
cG250 uptake and pimonidazole labelling or CAIX staining in head
and neck tumour models attributed to the large interval between
cG250 injection and immunohistochemical evaluation [44]. Pepsin
degradation of intact cG250 antibodies resulted in F(ab’)2 frag-
ments with a smaller molecular weight resulting in faster clear-
ance from blood and healthy tissues. Zirconium-89 labelled
cG250-F(ab’)2 fragments were found to spatially correlate with
CAIX expression [45]. Furthermore, fully human CAIX single-
chain variable fragment (scFv) minibodies have been generated
using phage-display technology. They recognize the extracellular
carbonic anhydrase domain, but do not inhibit CAIX activity and
do not bind to the other transmembrane enzyme CAXII [46].
Recently, near-infrared (NIR) fluorescent monoclonal antibodies
against CAIX and CAXII have been successfully tested for the
non-invasive detection of breast cancer metastasis [47]. A dual
labelled antibody combining indium-11 or iodine-125 nuclear with
NIR imaging has proven feasible for preoperative and intraopera-
tive detection of CAIX expressing renal cell carcinomas [48,49].
A second approach is the use of small molecules specifically tar-
geting the active site of CAIX. Several classes of small molecules
with low (nM) affinity have been extensively described, but due
to the high degree of homology among CA isotypes, smallmolecules are generally not specific for one isoform [50]. To pre-
vent interaction with the intracellular CA isoforms charged species
or bulky groups such as FITC, albumin or sugar moieties are added
to the small molecule. These strategies prevent transportation
across membranes, but do not guarantee selectivity between CAIX
and CAXII, both transmembrane enzymes with their catalytic
domains oriented extracellularly. Attempts to design specific
compounds targeting each isoform separately have been recently
reviewed [51].
We and others have demonstrated in vitro that small molecule
binding requires not only CAIX expression but also its hypoxic acti-
vation [52,53]. This offers a big advantage compared with antibod-
ies against CAIX, since these small molecules can distinguish cells
that are currently hypoxic from those that were previously hypox-
ic, while antibodies do not since their long half-life after reoxy-
genation [54]. In vivo, we have reported significant accumulation
of fluorescent sulfonamides in HT29 xenografts, which was cau-
sally related with tumour oxygenation. Furthermore, bound sul-
fonamide decreased rapidly upon tumour reoxygenation [55].
Similar results have been obtained using fluorescent acetazolamide
derivatives showing preferential targeting of CAIX overexpressing
SK-RC-52 renal cell xenografts [56]. Recently, a series of sulfon-
amide derivatives conjugated with NIR fluorescent dyes having
up to 50-fold higher selectivity for CAIX compared to the intracel-
lular and other transmembrane isoforms has been designed. High
tumoural uptake with little accumulation in other organs, except
for the kidneys, has been observed using fluorescence molecular
tomography [57]. Several synthesis strategies have been proposed
to enable nuclear imaging, however most attempts were not suc-
cessful in showing specific enhanced tumour uptake. We have syn-
thesized and evaluated a technecium-99 m labelled sulfonamide
for visualization of CAIX expression by SPECT imaging. Despite
favourable affinity values maximum tumour uptake was low
(<0.5% ID/g) even after varying physicochemical properties of the
molecules [58,59]. A range of sulfonamides conjugated metal com-
plexes have recently been designed for metallic radionuclide imag-
ing. Although high in vitro uptake was observed, cellular binding
between CAIX positive and negative cell lines was not obviously
different [60]. Besides metal chelation approaches, direct
fluorine-18 radiolabelling of CAIX targeted molecules has been
assessed. Several compounds have been synthesized, such as
7-(2-fluoroethoxy)coumarin (FEC) and U-104 [61], the tertiary
sulfonamides 4a-c [62] and VM4-037A [63]. Although all deriva-
tives showed good affinity for CAIX with excellent plasma stability,
uptake in HT-29 xenografts was minimal which precludes their
application as CAIX imaging agents.CAIX targeting
Inhibiting CAIX can be done either by the use of monoclonal
antibodies or with small molecule inhibitors. Antibody approaches
are mostly based on the concept of antibody dependent cell cyto-
toxicity (ADCC). A leading example is cG250, marketed as
RENCAREX, which is extensively investigated as an anticancer
immunotherapy [64]. Phase 1 and 2 trials have demonstrated
safety and efficacy as monotherapy or in combination with inter-
feron (IFN)-a for the treatment of renal cell carcinoma (RCC)
[65]. This antibody was also tested in the double-blind, placebo-
controlled phase 3 aRISER trial for adjuvant therapy of clear cell
RCC, but as announced by WILEX AG the antibody failed to meet
the primary endpoint, since no improvement in median disease-
free survival was observed compared to placebo. Several new anti-
bodies currently tested in preclinical settings show promising
results regarding anti-tumour effects [66,67].
Fig. 1. Window-of-opportunity trial concept implementing non-invasive hypoxia
imaging before and after drug administration followed by phase 1 or 2 trial
combining radiotherapy and experimental drug. Additional hypoxia imaging can be
included in step 3 for early response monitoring. HX4 hypoxia PET-CT images from
a patient with head and neck cancer are shown as proof of concept.
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using small molecules is an active field of research and has been
extensively reviewed [50,68,69]. Membrane-impermeable aceta-
zolamide derivatives [56] and aromatic sulfonamides [70] were
able to reduce tumour growth and proliferation. Treatment of
mammary-tumour bearing mice with CAIX-specific sulfonamide
and glycosylcoumarin inhibitors resulted in a significant reduction
in tumour growth and lung metastasis formation [71]. One of the
several potent CAIX inhibitors identified from a DNA-encoded
chemical library screen has shown high and specific accumulation
in tumour models [72]. A new class of sulfamate inhibitors proved
to be excellent candidates for low dosage anti-metastatic drugs
[73], but were ineffective in reducing primary tumour growth
[73,74]. Combining small molecules targeting CAIX with conven-
tional therapies might yield even better efficacy. Recently, a CAIX
dependent sensitizing effect of indanesulfonamides [75] and aceta-
zolamide [76] on respectively radio- and chemotherapy has been
demonstrated. Similarly combination of paclitaxel with orally
administered U-104 significantly affected primary tumour growth
and metastasis formation by reducing the breast cancer stem cell
population [77]. Nitroimidazole and sulfamide based dual target-
ing drugs reduced hypoxic extracellular acidification in vitro, inhib-
ited tumour growth at low dosage and sensitized tumours to both
radiation [78] and doxorubicin [79]. This dual-targeting strategy
appeared to be more effective than single targeting molecules.
Recently, a family of novel small-molecule drug conjugates com-
prising of a linker cleavable in the extracellular space and a potent
cytotoxic payload targeting CAIX has been designed and character-
ized. The disulfide-linked conjugate with maytansinoid DM1 as
cytotoxic payload and an acetazolamide derivative as the targeting
ligand has shown potent anti-tumour effects in renal cell carci-
noma models with only minimal toxicity [80]. These results indi-
cate that targeted delivery of potent cytotoxic agents using CAIX
directed ligands may provide therapeutic benefits over current
standard of care. The first clinical trial (NCT02215850) testing a
small molecule CAIX inhibitor, named SLC-0111, is currently ongo-
ing and is focused on testing the safety in subjects with advanced
solid tumours.Window-of-opportunity trial
Although there is a high number of new promising anti-cancer
agents under preclinical and clinical investigation, the success rate
of approved drugs for clinical practice has not been significantly
increased. Improved clinical trial designs, such as ‘window-of-op
portunity’ trials will help to select effective drugs at an earlier
stage and to identify patients which potentially will benefit of
the drug. In this trial, the patient agrees to delay combined conven-
tional anti-cancer therapy to first receive the experimental drug,
with the aim to obtain knowledge about anti-tumour activity in
a disease state that is not disturbed by previous or simultaneous
treatments [81]. The question has been raised whether these trials
should be more widely applied in early phases of drug develop-
ment knowing the progress in imaging and monitoring tumour
progression [82] to prevent expensive long-lasting classical clinical
testing of inefficacious drugs. Using this trial approach, hypoxia
imaging can be used as a biomarker of response, especially suitable
in the context of testing hypoxia (response) targeting drugs. Upon
patient inclusion, baseline hypoxia should be acquired followed by
the experimental targeting drug. A post-treatment hypoxia PET
scan will assess the effect of the single treatment by comparison
of the hypoxic fractions between the two scans (Fig. 1). This
window-of-opportunity trial can precede a phase 1 trial testing
safety of the experimental drug in combination with conventional
treatment, e.g. radiotherapy, or a randomized phase 2 clinical trial.We have used this concept preclinically to proof efficacy of the
hypoxia-activated cytotoxic prodrug TH-302. The hypoxic fraction
assessed with HX4 PET imaging in the rhabdomyosarcoma model
was significantly reduced at day 4 upon TH-302 treatment, while
vehicle treatment was ineffective. Additionally, TH-302 was not
only effective as monotherapy, but also sensitized tumours to a
single dose of radiation [30]. Similarly, BAY 87-2243, an inhibitor
of mitochondrial complex 1, resulted in reduced HIF-1a activity
and pimonidazole binding prior to radiotherapy improving local
tumour control [83,84]. Its efficacy has also been shown by a dra-
matic reduction in FAZA PET signal before significant changes in
tumour volume were observed [85]. Finally sunitinib treatment
resulted in improved tumour oxygenation as FAZA uptake in
Caki-1 renal cell xenografts [86] and in patients with soft-tissue
sarcomas [87] was significantly reduced during therapy. Upon
withdrawal of sunitinib therapy, FAZA uptake increased again,
indicating a rebound in tumour hypoxia. These examples clearly
highlight the importance of imaging the hypoxic fraction of
tumours to monitor treatment response.
Conclusions
Current clinically available hypoxia PET tracers, although show-
ing different characteristics, have proven to be reliable for evalua-
tion of tumour hypoxia. Much progress has been made in the
synthesis and evaluation of high affinity small molecules targeting
CAIX. Nevertheless, proper clinically-suited diagnostic tools are
still lacking. The window-of-opportunity trial concept implement-
ing non-invasive imaging to monitor treatment response is an
important tool to provide evidence of anti-tumour efficacy in
earlier stages of drug development.
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